Merck & Co., Inc.
MRK Healthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.
Follow MRK
Merck & Co., Inc. (MRK) Total debt
Merck & Co., Inc.'s total debt at the end of fiscal 2025 was $46.8B, up 35.7% from $34.5B in fiscal 2024. At the end of the quarter to 30 June 2026 it was $51.1B. Over the past ten years it has ranged from $19.8B (fiscal 2018) to $46.8B (fiscal 2025) — the current reading is the highest in ten years. Merck & Co., Inc. ranks 5th of 21 Drug Manufacturers General companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $46.8B | 35.66% |
| FY2024 | $34.5B | 2.31% |
| FY2023 | $33.7B | 17.18% |
| FY2022 | $28.7B | (6.34%) |
| FY2021 | $30.7B | 21.02% |
| FY2020 | $25.4B | 11.54% |
| FY2019 | $22.7B | 14.79% |
| FY2018 | $19.8B | (7.24%) |
| FY2017 | $21.4B | (12.03%) |
| FY2016 | $24.3B | 1.87% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $51.1B | 9.44% |
| Mar 2026 | $46.7B | (0.16%) |
| Dec 2025 | $46.8B | 16.97% |
| Sep 2025 | $40.0B | 17.67% |
| 42 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ABBV AbbVie Inc. compare | $70.8B |
| PFE Pfizer Inc. compare | $63.2B |
| AMGN Amgen Inc. compare | $57.3B |
| MRK Merck & Co., Inc. | $51.1B |
| NVS Novartis AG compare | $47.1B |
| JNJ Johnson & Johnson compare | $37.3B |
| AZN AstraZeneca PLC compare | $29.5B |
| GILD Gilead Sciences, Inc. compare | $26.2B |
| NVO Novo Nordisk A/S compare | $21.8B |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on MRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement